



## PRESS RELEASE

### **ONCODESIGN will present next generation targeted molecules for auto-immune and neurodegenerative diseases based on the Nanocyclix approach at the 9<sup>th</sup> Drug Discovery Chemistry conference in San Diego, CA**

**Dijon (France), April 17, 2014** – ONCODESIGN (FR0011766229 - ALONC), a biotechnology company serving the pharmaceutical industry in the discovery of new therapeutic molecules to fight cancer and other serious illnesses with no known efficient treatment, announces that it has been invited to present its progress related to Nanocyclix, a next generation kinase inhibitor technology applied in auto-immune and neurodegenerative diseases at the Drug Discovery Chemistry annual conference.

New data concerning Oncodesign's RIP2 and SIK2 macrocyclic kinase inhibitors will be presented by Dr. Jan Hoflack, Oncodesign's CSO, during the Conference session devoted to kinase inhibitor chemistry and the transformation of these molecules into innovative drugs.

The Cambridge Healthtech Institute's 9<sup>th</sup> annual conference will take place in San Diego (California) from April 23 to 25, 2014. This annual conference is attended by more than 500 world specialists in small molecule drug discovery, notably in the field of kinases, a domain that represents over 25% of big pharma research & development investments and that represents many of the most promising therapeutic intervention strategies.

Jan Hoflack, Chief Scientific Officer of ONCODESIGN, says: *"It is an honor for all of our teams to be invited to present the Nanocyclix platform derived inhibitor data to the worldwide community of kinase professionals. This represents a major recognition of our next generation kinase inhibitor technology that has led to novel small molecules for which we have identified the potential importance in auto-immune and neurodegenerative diseases. Lastly, for our partners, it provides validation of our approaches and brings tremendous hope for patients suffering from auto-immune and neurodegenerative diseases for which no effective treatment currently exists."*

**About ONCODESIGN:** [www.oncodesign.com](http://www.oncodesign.com)

Founded 19 years ago by Dr. Philippe Genne, the Company's CEO and majority shareholder, ONCODESIGN is a biotechnology company that maximizes the pharmaceutical industry's chances of success in discovering new therapeutic molecules to fight cancer and other serious illnesses with no known efficient treatment. Backed by unique experience acquired through more than 500 clients, including the world's largest pharmaceutical companies, and relying on a comprehensive technological platform combining state-of-the-art medicinal chemistry, advanced animal modeling and medical imaging, ONCODESIGN is able to predict and identify for every molecule, very upstream, its therapeutic use and its potential to become an efficient drug. Applied to kinase inhibitors, molecules that represent a market estimated at over 40 billion dollars in 2016 and accounting for almost 25% of the pharmaceutical industry's R&D investments, ONCODESIGN's technology has already enabled the targeting of 7 promising molecules with substantial therapeutic potential, in oncology and elsewhere, and the signing of partnerships, potentially worth €350 million in upfront payments should predefined milestones be reached, with pharmaceutical groups Sanofi, Ipsen and UCB. Based in Dijon, France, in the heart of the town's university and hospital hub, ONCODESIGN has 63 staff.

#### Contacts

##### **OncoDesign**

Philippe Genne  
CEO  
Tel.: +33 (0)3 80 78 82 60  
[investisseurs@oncodesign.com](mailto:investisseurs@oncodesign.com)

##### **NewCap.**

Investor Relations & Financial Communication  
Julien Perez / Emmanuel Huynh  
Tel.: +33 (0)1 44 71 98 52  
[oncodesign@newcap.fr](mailto:oncodesign@newcap.fr)